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Comprehensive geriatric assessment (CGA) is frequently used in oncology to measure the health status of
older adults with cancer, but it has not been studied in allogeneic hematopoietic cell transplantation (HCT).
We conducted a prospective pilot study of CGA in allogeneic HCT recipients aged 50 years to examine the
prevalence of vulnerabilities in this population. Patients aged 50 years eligible for HCT were enrolled. CGA
consisted mainly of self-reported, performance-based, and chart-extracted measures evaluating domains of
comorbidity, physical and mental function, frailty, disability, and nutrition. Of 238 eligible patients, 166
completed CGA and underwent HCT. Only 1% had a Zubrod Performance Status score >1; 44% had high
comorbidity deﬁned by the Hematopoietic Cell Transplantation Comorbidity Index, and 66% had high
comorbidity deﬁned by the Cumulative Illness Rating ScaleeGeriatrics. The presence of additional vulnera-
bility was frequent. Disability was present in 40% by Instrumental Activities of Daily Living. Self-reported
physical and mental function were signiﬁcantly lower than population age group norms, 58% were pre-
frail, and 25% were frail. Among those with Zubrod Performance Status score of 0, 28% demonstrated
disability, 58% were pre-frail, 15% were frail, 35% reported low physical function, and 55% reported low mental
function. CGA uncovers a substantial prevalence of undocumented impairments in functional status, frailty,
disability, and mental health in older allogeneic HCT recipients.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION have been the main tools used by transplantation physicians
The advent of reduced-intensity and nonmyeloablative
preparative regimens, coupled with substantial improve-
ments in supportive care, have resulted in increasing
numbers of older adults referred for allogeneic hema-
topoeitic cell transplantation (HCT) [1]. As the population
continues to age and transplantation practices are further
reﬁned, this number likely will continue to rise. Over the past
decade, the oncology community has begun to partner with
geriatricians to integrate geriatric principles into the care of
older adults with cancer [2]. An example of this effort is the
application of comprehensive geriatric assessment (CGA),
deﬁned by geriatricians as “a multidisciplinary evaluation in
which themultiple problems of older persons are uncovered,
described, and explained, if possible, and in which the
resources and strengths of the person are catalogued, need
for services assessed, and a coordinated care plan developed
to focus interventions on the person’s problems” [3], into
traditional oncology practice. Moreover, accumulating data
show that CGA predicts morbidity and mortality and may
facilitate guided interventions in older cancer patients [4-7].
Allogeneic HCT is an aggressive, curative intent approach
typically used in presumably ﬁt individuals aged <75 years.
Age, performance status, and, more recently, comorbiditydgment on page 433.
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12.11.006to assess recipient health status and determine suitability for
HCT [8]. A more comprehensive evaluation obtained by
CGA may reveal occult limitations, allow for meaningful
comparisons to non-transplantation or general age-matched
controls, improve prognostication, and ultimately identify
problems that might be modiﬁable in the peri-trans-
plantation period. We performed a prospective pilot study of
CGA before allogeneic HCT, with the initial aim of describing
the prevalence and severity of vulnerabilities captured in
otherwise transplantation-eligible older adults.
METHODS
Patients
Patients scheduled to undergo allogeneic HCT who were at least 50
years old and able to complete the study questionnaires were eligible for
this study. A threshold age of 50 years was chosen because it is the tradi-
tional age at which conditioning regimen intensity may be reduced [9].
Conditioning therapy was to begin within 1 month of study enrollment. Our
ﬁnal analysis included only those subjects who completed the majority of
CGA and received pre-transplantation conditioning. Suitability for HCT was
determined solely by the treating physician and patient. Results of CGAwere
not available to the treating physician and did not affect any treatment
decisions. All patients provided written informed consent for this Institu-
tional Review Boardeapproved protocol.
HCT Treatment Plan
Conditioning regimens were selected based on physician and patient
preference. Of note, our institutional protocols frequently use alemtuzumab
i.v. at a total dose of 100 mg before stem cell infusion [10-12]. HLA matching
by high-resolution techniques was performed at HLA-A, HLA-B, HLA-C, and
HLA-DRB1. Peripheral blood progenitor cells were preferred and were
collected after granulocyte colony-stimulating factor mobilization.Transplantation.
Table 1
Domains and Measures of CGA
Domain Measure Normal Value Description
Comorbidity CCI 0 Estimates life expectancy based on presence or absence of 16 comorbid medical conditions.
KF Scale 0 Categorizes comorbid conditions in different organ systems by severity.
HCT-CI 0 Estimates risk of nonrelapse mortality 2 years after transplantation based on pretransplantation
comorbid diagnoses and organ dysfunction built on the backbone of the CCI.
CIRS-G 0 Comprehensive predictive index measuring illness severity on a scale of 0-4 across 14 organ
systems, with a maximum score of 56.
Functional status Zubrod PS 0 Assesses ambulatory and functional status among cancer patients determined by the health care
professional on a scale of 0-5.
FI 0 Functional measure of frailty incorporates 5 parameters, 2 performance-based (walk speed and grip
strength) and 3 self-reported (physical activity, exhaustion, and weight). A threshold value
determines frail or not for each question.
Katz ADL 12 Measures basic self-care skills required to maintain independence in the home over 6 areas (eating,
dressing, grooming, ambulating, getting out of bed, bathing) on a 3-point Likert scale (1-3).
Lawton IADL 14 Measures complex skills required to maintain independence in the community on 7 areas
(telephone, driving, shopping, meal planning, housekeeping, taking medication, and money
management) on a 3-point Likert scale (0-2).
SF-36 PCS 100 Aggregated measure of physical health derived from a 36-item validated health-related quality of
life questionnaire.
Mental health SF-26 MCS 100 Aggregated measure of mental health derived from a 36-item validated health-related quality of life
questionnaire.
Nutritional status BMI 18.5-24.9 Weight in kilograms/(height in meters)2
Albumin, mg/dL 3.5 Marker for nutritional status
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A clinical research assistant or registered nurse performed the CGA. The
assessment was usually completed before conditioning; however, for
logistical reasons, in one-third of the subjects, CGA was performed on
admission or 1 to 2 days after the start of conditioning. The CGA integrates
validated measures across multiple domains [13-21], as detailed in Table 1.
Comorbidity was assessed using numerous tools developed for evaluating
comorbid medical burden as the focus of HCT studies. Comorbidity assess-
ment scales included the Charlson Comorbidity Index (CCI), Kaplan-
Feinstein (KF) Scale, Hematopoietic Cell Transplantation Comorbidity
Index (HCT-CI), and the Cumulative Illness Rating ScaleeGeriatrics (CIRS-G).
For each subject, comorbid medical conditions were extracted from the
medical record, and ﬁndings were veriﬁed by a physician (A.A. or L.M.). A
comorbid conditions questionnaire supplemented the medical record to
complete the CIRS-G, which requires more detailed information than typi-
cally is readily available. The primary malignancy and cytopenias were not
included when scoring the CIRS-G, because these ﬁndings were common
and inseparable from the primary malignancy and its treatment. The
treating physician and interviewer scored Zubrod Performance Status (PS)
separately. In addition to PS, functional status and disability were assessed
using highly validated instruments, including Katz Activities of Daily Living
(ADL), Lawton Instrumental Activities of Daily Living (IADL), and the Physical
Component Summary of the SF-36 (SF-36 PCS) for self-reported physical
function. The Fried Frailty Index (FI) allowed determination of frailty. The
mental component summary of the SF-36 (SF-36 MCS) documented self-
reported mental state. Serum albumin level and body mass index (BMI)
quantiﬁed nutritional status.Statistical Considerations
Descriptive statistics were used to summarize the characteristics of
patients, including baseline scores for each instrument and measures ofFigure 1. Diagram of study accrual.variation. Categorical variables were compared using the chi-square test or
Fisher exact test as appropriate. Pearson’s correlation coefﬁcient enabled
correlation for continuous variables. The SF-36 PCS and SF-36 MCS were
scored using standard algorithms of the SF-36 instrument [22] and
compared with population age group norms [23]. Statistical analyses were
performed using Stata version 11.0 (StataCorp, College Station, TX).
RESULTS
Between April 2005 andMarch 2011, 228 patients met the
eligibility criteria, 197 of whom consented to participate. Of
these 197, 166 completed the CGA, underwent HCT, and were
included in our analysis (Figure 1). Of the 31 patients who
provided signed consent and did not complete CGA, 5 did not
undergo HCT, 7 did not complete the interview by choice,
and 19 did not complete the interview for unknown reasons.
In summary, A total of 166 of the 228 initially eligible
patients (78%) completed the CGA. Table 2 presents demo-
graphic data for these patients. The median patient age was
58 years (range, 50-73 years), with 100 patients (62%) aged
50 to 59.9 years, 62 (38%) aged 60 to 69.9 years, and 2 (4%)
aged 70 years. In total, 27 patients (16%) were aged >65
years. The median time to complete the entire geriatric
assessment, including questionnaires and objective
measurements, was 20 minutes (range, 15-27 minutes), as
determined in a subset of 8 consecutive patients. Physician
scoring of the 4 comorbidity tools required a median of 8
minutes (range, 4-11 minutes), whereas the FI was consis-
tently calculated in 2minutes or less. Table 3 summarizes the
key ﬁndings of the CGA.
Zubrod PS
PS rated by the treating physician frequently showed little
impairment, as demonstrated by a score of 0 in 115 patients
(70%), 1 in 47 patients (29%), or 2 in 2 patients (1%). The
interviewer’s assessment of PS was strongly correlated with
that of the treating physician (P < .0001).
Comorbidity
High comorbidity was present in 44 patients (27%) by the
KF, in 64 (39%) by the CCI, in 73 (44%) by the HCT-CI, and in
109 (66%) by the CIRS-G. In contrast, 26 patients (16%) had an
HCT-CI score of 0, and 63 (40%) had an HCT-CI score of 1-2,
whereas only 2 patients (1%) had a comorbidity score of 0 by
Table 2
Baseline Demographic Data
Characteristic No. (%)
Evaluable patients 166 (100)
Age group, y
50-59 100 (60)
60-69 62 (38)
70þ 4 (2)
Sex
Male 108 (65)
Female 58 (35)
Race
Caucasian 154 (93)
African American 8 (5)
Other 4 (2)
Primary disease
Acute myelogenous leukemia/myelodysplastic syndrome 95 (57)
Non-Hodgkin lymphoma 30 (18)
Chronic myelogenous leukemia 9 (5)
Chronic lymphocytic leukemia 9 (5)
Acute lymphoblastic leukemia 10 (6)
Other 13 (9)
Disease risk
Not in remission/response 79 (47)
Remission/controlled 87 (53)
Stem cell source
Peripheral blood 142 (86)
Bone marrow 3 (2)
Cord blood* 21 (8)
Donor type
Matched related 74 (45)
Matched unrelated 61 (37)
Mismatched/cord 31 (19)
Preparative regimen
Ablative 38 (23)
Reduced-intensity/nonmyeloablative 128 (77)
Previous HCT 19 (11)
* Cord blood/haploidentical stem cells.
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lated (P < .001). However, 30% (20 of 66) with an interme-
diate HCT-CI score of 1 to 2 and 8% (2 of 26) with an HCT-CI
score of 0 had high comorbidity by the CIRS-G.
Physical Function and Disability
Self-reported physical function by the SF-36 PCS was
signiﬁcantly lower than general population and age-groupTable 3
Results of Pretransplantation CGA
Domain with Measure No. Tested Mean SD M
Comorbidity
CCI 164 0.6 0.9 0
KF 165 1 0.9 1
HCT-CI 165 2.2 1.8 2
CIRS-G 165 7.3 3.7 8
Functional status
Zubrod PS: assistant 151 0.4 0.6 0
Zubrod PS: physician 164 0.3 0.5 0
FI 111 1.6 1.2 1
ADL 164 11.9 0.5 12
IADL 164 13.1 1.9 14
SF-36 PCS 163 41.7 8.3 42
Mental health
SF-36 MCS 164 37.8 7.6 38
Nutritional status
BMI 158 28.3 5.7 27
Albumin, mg/dL 160 4 0.4 4norms (Figure 2); 73 (45%) scored at least 1 SD below the
population mean. Few patients had limitations in ADL (ie,
basic self-care skills), but 65 patients (40%) reported
impaired IADL (ie, skills necessary to maintain
independence).
Frailty
All 5 categories of the FI were evaluable in 111 patients
(67%). Impairment of the 2 performance-based measures of
walking speed and grip strength was demonstrated by 28%
and 22%, respectively. Regarding the self-report measures,
31%met the criteria for exhaustion, 60% reportedweight loss,
and 31% reported a decline in physical activity. Calculation of
total frailty scores showed that 57 patients (51%) met pre-
frail criteria (1 or 2 impairments), and 28 (25%) demon-
strated 3 impairments, meeting the formal criteria for frail.
Mental Function
Self-reported mental function by the SF-36 MCS revealed
signiﬁcantly worse mental health relative to general pop-
ulation normative scores and age group norms (Figure 2),
with 96 patients (59%) scoring at least 1 SD below the pop-
ulation mean.
Nutritional Markers
Objective measures rarely demonstrated undernutrition,
given that only 21 patients (13%) had a low serum albumin
level (<3.5 g/dL), and 2 patients (1%) had a BMI <18.5.
However, 60% reported a weight loss of >10% within the past
6 months by the FI. Using BMI criteria, a fairly high propor-
tion were either overweight (42%) or obese (31%).
Comparison with Standard Pretransplantation
Parameters
We sought to evaluate the sensitivity of detecting vul-
nerabilities by CGA relative to the routine pretransplantation
health assessment measures of age, PS, and HCT-CI.
Age
Older age was not associated with increased limitations
by standard transplantation measures or CGA. Older age asedian Range Proportion Impaired
Impairment Threshold No. (%)
0-6 1 64 (39)
0-3 2 44 (27)
0-9 3 73 (44)
0-17 6 109 (66)
0-3 1 40 (25)
2 7 (4)
0-2 1 47 (28)
2 2 (1)
0-4 1-2 57 (51)
3 28 (25)
8-12 <12 13 (8)
5-14 <14 65 (40)
22-56 <40 73 (45)
11-55 <40 96 (59)
.8 14.7-56.5 <18.5 2 (2)
30 49 (31)
2.2-4.8 <3.5 21 (13)
Figure 2. Adjusted mean SF-36 PCS (A) and SF-36 MCS (B) scores for alloge-
neic HCT recipients compared with population age group norms. *Allogeneic
HCT recipients aged 50 years.
Figure 3. CGA impairments by performance status.
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(P ¼ .52) or more comorbidity by the HCT-CI (P ¼ .57).
Moreover, therewere no signiﬁcant differences in PS (P¼ .76)
or HCT-CI (P¼ .30) among patients aged60 years relative to
those aged 50 to 59. Likewise, relative to those aged 50 to 59,
patients aged60 years demonstrated similar frequencies of
low physical function (P ¼ .22), frailty (P ¼ .45), IADL
disability (P ¼ .62), low mental function (P ¼ .13), and
undernutrition (P ¼ .41).PS
Worse PS (PS 1 relative to PS 0) was correlated with lower
self-reported physical function (P < .001), increased frailty
(P ¼ .001), disability (P ¼ .01), and undernutrition (P ¼ .002).
In contrast, PS showed no association with mental function
(P¼ .29). Figure 3 shows impairments in CGA domains for the
overall cohort relative to those patients with a PS of 0. The 72
patients with a preserved PS of 0 demonstrated a surpris-
ingly high prevalence of limitations; 35% reported physical
function impairment, 58% were pre-frail, 15% were frail, 28%
had disability, and 55% reported low mental function.HCT-CI
High comorbidity (HCT-CI 3) was associated with lower
self-reported physical function (P ¼ .004) but was not
signiﬁcantly associated with disability (P ¼ .88), frailty
(P ¼ .91), low mental function (P ¼ .44), or poor nutrition
(P ¼ .21). Frailty was present in 11 patients (24%) with high
comorbidity by the HCT-CI, in 15 patients (27%) withintermediate morbidity, and in 2 patients (10%) with low
comorbidity. Additional CGA limitations were frequently
found in those with low or intermediate HCT-CI scores; 35%
reported low physical function, 62% had disability, and 56%
reported low mental function.DISCUSSION
To the best of our knowledge, this study is the ﬁrst
application of CGA in allogeneic HCT recipients aimed at
determining the feasibility and baseline prevalence of CGA
vulnerabilities in HCT-eligible adults aged 50 years. The
inclusion of CGA into pre-transplantation assessment was
accepted by the vast majority of the older adults undergoing
allogeneic HCT, with 73% of eligible transplantation recipi-
ents at our institution completing the CGA. Furthermore, the
median time required for a trained nurse or research assis-
tant RA to administer the CGA was not prohibitive. Equally
reassuring is that the staff time required to score each tool
was on the order of a couple of minutes, including the FI,
which was consistently calculated in 2 minutes or less. This
suggests that CGA can be readily incorporated into the HCT
setting.
The CGA identiﬁed numerous vulnerabilities not captured
by traditional health assessment measures of PS and
comorbidity. For example, although 99% of these HCT
recipients had a Zubrod PS of 0 or 1 (equivalent to a Karnof-
sky PS of 70%-80% or higher), indicating good health, the FI
classiﬁed 58% as pre-frail and 25% as frail by the most widely
validated tool of frailty [17]. Interestingly, the prevalence of
pre-frail and frail quantitatively exceeded the 30% to 40%
pre-frail and 4% to 15% frail rates reported in population-
based studies of adults aged 64-74 years [24,25]. Similarly,
45% reported low physical function, and 40% demonstrated
at least 1 disability by the IADL in tasks necessary for
complete independence (eg, money management, shop-
ping). Substantially reduced mental health was uncovered in
58% of the population, a ﬁnding that may have otherwise
gone unnoticed.
Comorbidity scales have rapidly emerged as tools to ﬁll
the large void of limited health status measures in HCT, with
the HCT-CI as the standard. Tabulation of comorbid medical
conditions represents an integral component of a CGA, given
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older patients with cancer [26], as well as in transplantation
recipients [27,28]. Comorbidity alone does not provide
a comprehensive overview of baseline health status in older
adults, however, as evidenced by the substantial limitations
in functional and mental status captured by CGA in patients
without a high comorbidity burden. As reported previously,
the HCT-CI detected more comorbidity than older tools, such
as the CCI or KF Scale. However, greater sensitivity for
comorbid conditions was demonstrated by the CIRS-G
(median score, 8) relative to the HCT-CI (median score, 2).
The CIRS-G reﬂects common problems in older adults and
has been studied in older patients with cancer [29]. The
foregoing data support our general ﬁnding that the tools
developed for older adults that are included in CGA are
highly sensitive in a younger allogeneic HCT population as
well and uncover a large number of undocumented
vulnerabilities.
This study has several limitations. As a single-center pilot
study across hematologic malignancies, donor sources, and
conditioning regimens, conﬁrmatory studies are needed. The
use of highly validated tools and the added sensitivity of CGA
reported in numerous non-transplantation studies argue in
favor of the reproducibility of our results [2,30,31]. Our
decision to include transplantation recipients aged 50 and
older, as opposed to the more traditional 60 or 65 years,
resulted in a younger cohort, with a median age of 58, rela-
tive to other CGA studies. Of note, conditioning regimen
intensity may be reduced arbitrarily based solely on age 50
years [9]. The use of a self-reported quality-of-life tool (ie,
SF-36) is not typical in a CGA. Such tools have gained
acceptance as not only outcome measures for health-related
quality of life but also as prognostic markers that may be
superior to comorbidity [32,33]. Perhaps most importantly,
we did not cover all domains of interest in this exploratory
study, such as cognitive impairment, polypharmacy, and
caregiver support, which are often included in a CGA.
As transplantation is offered to increasingly older adults,
there has been widespread recognition of the need to
understand “biological” age rather than relying solely on
chronological age. Applying the principles of CGA to trans-
plantation recipients satisﬁes this need and offers several
beneﬁts. A richer and more in-depth understanding of the
health status of transplantation recipients using standard-
ized CGA tools facilitates comparisons with non-trans-
plantation populations and more appropriate generalization
of outcomes. As demonstrated in the present study, CGA also
provides meaningful clinical information that might go
undetected otherwise. The prognostic value of CGA in allo-
geneic HCT needs further study, given that previous reports
demonstrating the capability of CGA to predict mortality
have typically involved older adults with advanced solid
tumors. In addition, in the setting of highly intensive therapy
that requires lengthy hospitalization and recovery, subtle
vulnerabilities detected by CGA may contribute signiﬁcantly
to transplantation morbidity. Finally, characterizing limita-
tions also allows for the development of interventions to
abrogate attendant complications. For example, mild reduc-
tions in self-reported and/or performance-basedmeasures of
functional status may inﬂuence recommendations for dedi-
cated programs of exercise and close monitoring tominimize
geriatric syndromes such as delirium, falls, and functional
decline.
In summary, this pilot study of geriatric assessment in
allogeneic HCT recipients demonstrates that CGA is feasiblein the transplantation setting and that comprehensive health
assessment in older transplantation recipients uncovers
frequently undocumented vulnerabilities. Larger, multi-
institutional studies are needed to conﬁrm these ﬁndings
and evaluate the prognostic and therapeutic potential of CGA
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